INTRODUCTION
Chronic hepatitis B virus (HBV) infection is associated with a large spectrum of liver diseases, ranging from a low viremia inactive carrier state to chronic active hepatitis, which may subsequently evolve towards cirrhosis and hepatocellular carcinoma (HCC). Morbidity and mortality are linked to the persistence of viral replication and hepatic complications develop in 15 to 40 of patients chronically % % infected with HBV. Overall, HBV-related end-stage liver disease and HCC are responsible for over 750,000 deaths worldwide per year (5 ) .
HBV DNA detection and quantification is essential to diagnose ongoing HBV infection and to establish the prognosis of related liver disease, influences the decision to treat, and is indispensable to monitor the virological response to antiviral therapy and the emergence of Pleasanton, California). This assay was found to be sensitive, specific, and reproducible, and to accurately quantify HBV DNA levels in patients chronically infected by HBV genotypes A to F ( ). However, this assay could only be used for HBV DNA quantification in 2 plasma.
A second version of the CAP/CTM assay (v2.0) has been recently released. Several changes have been made; in particular, the assay can be used on both serum and plasma and it requires 650 L of sample instead of 850 L. Its claimed dynamic range of quantification is 
Analytical sensitivity
To determine the analytical sensitivity of the assay, the NAP-HBV2E4 standard was serially diluted from 50 IU/mL (1.7 Log IU/mL) 10 to 6.25 IU/mL (0.8 Log IU/mL). Twenty-one replicates of each HBV DNA concentration were tested in different experiments.
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Specificity
The specificity of CAP/CTM v2.0 was assessed by testing the 103 and 97 clinical specimens from groups A and B.
Precision and reproducibility
To assess precision (intra-assay reproducibility), each sample in the OptiQuant HBV DNA standard panel was tested in triplicate. To ™ assess inter-assay reproducibility, the low-positive control (LPC) and the high-positive control (HPC) provided with the kits were tested 18 times in the corresponding runs on different days.
Linearity, accuracy and influence of the HBV genotypes
The linearity of quantification in CAP/CTM v2.0 was assessed by testing the 7 members of the OptiQuant HBV DNA standard 
Assessment of equal quantification in serum and plasma
The 51 plasma and 51 serum specimens sampled at the same time point in patients from group D were tested with version 2.0 of the CAP/CTM assay and the results were compared. These samples were tested in parallel with CAP/CTM v1.0 in plasma and with bDNA in both serum and plasma. 
Statistical analysis
Descriptive statistics are shown as the mean standard deviation (SD) or the median and interquartile range as appropriate.
±
Comparisons between groups were made using the Kruskall-Wallis test or Mann-Whitney test. The relationship between quantitative variables was studied by means of regression analysis. values <0.05 were considered significant. P
RESULTS
Intrinsic performance of the CAP/CTM v2.0 assay
Analytical sensitivity
The lower limit of detection of the assay is claimed to be 20 IU/mL by the manufacturer. Twenty-one tested replicates containing 50 IU/mL (1.7 Log IU/mL), 25 IU/mL (1.4 Log IU/mL) and 12.5 IU/mL (1.1 Log IU/mL) tested HBV DNA-positive in CAP-CTM v2.0. 
Precision and reproducibility
As shown in , the intra-assay coefficients of variation (precision) and inter-assay coefficients of variation (reproducibility) Table 1 ranged from 1.10 to 3.07 and 0.82 to 2.95 , respectively. HBV DNA levels were measured in the 51 samples from patients from group C, infected with HBV genotypes A to F. Thirty-eight of them (75 ) fell within the dynamic range of quantification of the CAP/CTM v2.0 assay, whereas the remaining 13 samples (25 ) had to % % be retested after dilution. As shown in , there was a significant relationship between the HBV DNA levels obtained with difference, including three (two with genotype A and one with genotype B) that were underquantified and three (one with genotype D and two with genotype E) that were overquantified with CAP/CTM v2.0 relative to bDNA. However, the individual differences between CAP/CTM v2.0 and bDNA values were always below 1.0 Log IU/mL in these samples.
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Box plots of individual differences between the two methods are shown for each genotype in . They confirm the global, Figure 3B moderate underestimation of HBV DNA levels by CAP/CTM v2.0 compared to the bDNA method, independently of the HBV genotype.
The median differences were 0.17 Log IU/mL for genotype A, 0.37 Log IU/mL for genotype B, 0.32 Log IU/mL for genotype C, because only three samples were tested.
HBV DNA monitoring in patients receiving antiviral therapy
Sixteen patients chronically infected with HBV (4 with genotype A, 5 with genotype C, 1 with genotype D and 6 with genotype E) included in group D were serially sampled on treatment with nucleoside/nucleotide analogues. For these patients, 51 plasma and 51 serum specimens sampled at the same time were available. The 51 plasma samples were tested in parallel with CAP/CTM v1.0, CAP/CTM v2.0 and bDNA, while the 51 serum samples were tested with CAP/CTM v2.0 and bDNA. As shown in , CAP/CTM v2.0 equally Table 2 quantified HBV DNA in plasma or serum (mean difference range: 0.04 to 0.11 Log IU/mL, according to the HBV genotype). As shown 10 in , both versions of the CAP/CTM assay equally quantified HBV DNA levels in plasma (mean difference range: 0.04 to 0.20 Log Table 3 IU/mL, according to the HBV genotype). 10 shows individual examples of HBV DNA level kinetics measured with the two versions of the CAP/CTM assay and bDNA in Figure 4 patients infected with HBV genotypes A, C, D and E. The differences between CAP/CTM v2.0 and bDNA were always less than 0.5 Log IU/mL, except in two patients. Indeed, in one patient infected with genotype C (Pt non 7) and in one patient infected with genotype E (Pt 10 non 11), HBV DNA levels were underestimated by CAP/CTM v2.0 by 1.38 and 1.41 Log IU/mL on average, respectively, relative to − − 10 the third-generation bDNA assay ( ). Figure 4 
Target sequence analysis in clinical specimens from patients included in the longitudinal analysis
The nearly full-length preC-C region of the HBV genome, which is the target of CAP/CTM primers and probes, was sequenced in the 16 patients from group D in order to determine the possible role of nucleotide sequence polymorphisms in the underestimation of HBV DNA levels in patients 7 and 11. In spite of the presence of polymorphisms in the pre-C region, no nucleotide signature was found to explain underestimation of HBV DNA levels in the two patients (data not shown). In the present study, we showed that CAP/CTM v2.0 has an excellent analytical sensitivity, with a lower limit of detection of the order of the value claimed by the manufacturer, i.e. 20 IU/mL. This assay was also precise and reproducible, as previously reported ( ). In 6 addition, we observed a strong, significant relationship between HBV DNA levels measured by CAP/CTM v2.0 and the third-generation bDNA-based assay. The use of the third-generation bDNA assay as a comparator was justified by the fact that this assay is accurate, precise, reproducible, well-calibrated to the World Health Organization HBV DNA standard and quantifies HBV DNA levels independently of the HBV genotype, due to the presence of a large number of capture and extender probes located at various positions along the HBV genome ( , ). There was also an excellent correspondence between versions 1.0 and 2.0 of the CAP/CTM assay in 7 11 plasma in our experiments, regardless of the HBV genotype.
Similarly to the first-generation CAP/CTM assay, we observed a modest underestimation of HBV DNA levels in the 6 members of the standard panel, mainly above an HBV DNA level of 5.0 Log IU/mL. This finding was confirmed in clinical samples when CAP/CTM 10 v2.0 values were compared to values obtained with the bDNA assay. This modest underestimation was independent of the HBV genotype and has no implications in clinical practice. Indeed, in contrast with HCV therapy, where accurate quantification is needed to make treatment decisions ( ), this technical issue has little clinical implication in HBV therapy with nucleoside/nucleotide analogues, as the 3 goal of this treatment is to maintain HBV DNA levels in the long term below the lower limit of quantification of the assay.
In two cases, however, we observed a substantial underestimation of HBV DNA levels in CAP/CTM relative to bDNA. These samples contained HBV genotypes C and E, respectively. The underestimations were consistent in several serial samples from the two patients, suggesting that they were due to the nature of the infecting HBV strain in these patients. This may be seen when mismatches occur between the primers and/or the Taqman probe and the target viral sequence as a result of natural nucleotide polymorphisms ( ). We thus 1 sequenced the target region (preC-C) in order to identify whether nucleotide polymorphisms could differentiate the patients who were equally quantified in CAP/CTM and bDNA from these two individuals. No sequence signature has been identified that could explain underestimation of HBV DNA levels in these two patients.
The main improvement in the second generation of the CAP/CTM assay is the possibility to quantify HBV DNA in both serum and plasma, whereas the first-generation assay was for plasma only. We thus assessed whether values obtained in plasma with both versions of the assay and in serum and plasma with CAP/CTM v2.0 were concordant. As shown here, there was an excellent correspondence between the values obtained in different matrices. In addition, serial follow-up in patients from group D showed almost perfect superimposition in all cases, confirming that CAP/CTM v2.0 can be used equally on serum or plasma samples in clinical practice.
In conclusion, this study shows that the new version of the CAP/CTM assay is sensitive, specific and reproducible, and that it accurately quantifies HBV DNA in both plasma and serum samples from patients with chronic HBV infection. Quantification is linear over the full dynamic range of quantification, which covers values observed in both treated and untreated patients with chronic hepatitis B.
However, the upper limit of quantification (8.2 Log IU/mL) is still too low to cover the full range of possible values. Any sample falling 
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Figure 2
Correlation between HBV DNA levels measured by CAP/CTM v2.0 and bDNA (A), and CAP/CTM v2.0 and v1.0 (B) in 51 clinical samples (group C) containing HBV genotypes A (n 12), B (n 9), C (n 8), D (n 9), E (n 10) and F (n 3). Table 1 Intra-assay (precision) and inter-assay reproducibility of CAP/CTM v2.0. For intra-assay reproducibility, the seven members of the standard panel (NAP-000 to NAP-HBV2E7) containing no HBV DNA up to 2 10 IU/mL, i.e. 7.3 Log IU/mL, respectively, have been tested in triplicate in the same experiment. For inter-assay reproducibility, the assay low positive control (LPC) and high positive 
